PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting

被引:6
作者
Wojtkowska, Izabela [1 ]
Tysarowski, Andrzej [2 ]
Seliga, Katarzyna [2 ]
Siedlecki, Janusz A. [2 ]
Juraszynski, Zbigniew [3 ]
Marona, Milosz [1 ]
Greszata, Lidia [1 ]
Skrobisz, Anna [1 ]
Kaminski, Karol [4 ]
Sawicki, Robert [4 ]
Stepinska, Janina [1 ]
机构
[1] Inst Cardiol, Intens Cardiac Therapy Clin, PL-04628 Warsaw, Poland
[2] Inst Oncol, Dept Mol Biol, PL-02781 Warsaw, Poland
[3] Inst Cardiol, Dept Cardiosurg & Transplantol, PL-04628 Warsaw, Poland
[4] Med Univ Bialystok, Dept Cardiol, PL-15276 Bialystok, Poland
关键词
TROGLITAZONE; ATHEROSCLEROSIS; ROSIGLITAZONE; DYSFUNCTION; MORTALITY;
D O I
10.1155/2014/242790
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Genetic research has elucidated molecular mechanisms of heart failure (HF). Peroxisome proliferator-activated receptors (PPARs) seem to be important in etiology of HF. The aim of study was to find the correlation between PPAR.. expression during development of HF in patients and coronary artery disease (CAD) after coronary artery bypass-grafting (CABG). Methods and Results. We followed up 157 patients (mean age 63) with CAD without clinical, laboratory, or echo parameters of HF who underwent CABG. Clinical and laboratory status were assessed before CABG and at 1, 12, and 24 months. During CABG slices of aorta (Ao) and LV were collected for genetic research. HF was defined as LVEF <40% or NT-proBNP >400 pg/mL or 6MWT <400 m. Patients were divided into 2 groups: with and without HF. PPAR gamma expression in Ao and LV was not increased in both groups at 2-year follow-up. Sensitivity of PPAR.. expression in Ao above 1.1075 in detection of HF was 20.5% (AUC 0.531, 95% CI 0.442-0.619). Positive predictive value (Ppv) was 85.7%. Sensitivity and specificity of PPAR gamma expression in the LV in detection of HF were 58% and 92.9%, respectively (AUC 0.540, 95% CI 0.452-0.626). Ppv was 73.2%. Conclusion. PPAR gamma expression in Ao and LV was comparable and should not be used as predictive factor for development of HF in patients with CAD after CABG.
引用
收藏
页数:5
相关论文
共 24 条
  • [1] Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions
    Anderson, RD
    Ohman, EM
    Holmes, DR
    Harrington, RA
    Barsness, GW
    Wildermann, NM
    Phillips, HR
    Topol, EJ
    Califf, RM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (04) : 936 - 941
  • [2] Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice - Pleiotropic effects on CD36 expression and HDL
    Chen, Z
    Ishibashi, S
    Perrey, S
    Osuga, J
    Gotoda, T
    Kitamine, T
    Tamura, Y
    Okazaki, H
    Yahagi, N
    Iizuka, Y
    Shionoiri, F
    Ohashi, K
    Harada, K
    Shimano, H
    Nagai, R
    Yamada, N
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) : 372 - 377
  • [3] PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts
    Chintalgattu, Vishnu
    Harris, Gregory S.
    Akula, Shaw A.
    Katwa, Laxmansa C.
    [J]. CARDIOVASCULAR RESEARCH, 2007, 74 (01) : 140 - 150
  • [4] Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
    Collins, AR
    Meehan, WP
    Kintscher, U
    Jackson, S
    Wakino, S
    Noh, G
    Palinski, W
    Hsueh, WA
    Law, RE
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) : 365 - 371
  • [5] Delea T., 2002, J AM COLL CARDIOLOGY, V39
  • [6] Coronary artery disease as the cause of incident heart failure in the population
    Fox, KF
    Cowie, MR
    Wood, DA
    Coats, AJS
    Gibbs, JSR
    Underwood, SR
    Turner, RM
    Poole-Wilson, PA
    Davies, SW
    Sutton, GC
    [J]. EUROPEAN HEART JOURNAL, 2001, 22 (03) : 228 - 236
  • [7] Cardiac and glycemic benefits of troglitazone treatment in NIDDM
    Ghazzi, MN
    Perez, JE
    Autonucci, TK
    Driscoll, JH
    Huang, SM
    Faja, BW
    Whitcomb, RW
    [J]. DIABETES, 1997, 46 (03) : 433 - 439
  • [8] Therapeutic Implications of PPARγ in Cardiovascular Diseases
    Hasegawa, Hiroshi
    Takano, Hiroyuki
    Komuro, Issei
    [J]. PPAR RESEARCH, 2010, 2010
  • [9] Long term prognosis after CABG in relation to preoperative left ventricular ejection fraction
    Herlitz, J
    Karlson, BW
    Sjöland, H
    Brandrup-Wognsen, G
    Haglid, M
    Karlsson, T
    Caidahl, K
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 72 (02) : 163 - 171
  • [10] Comparison of in-hospital, and one-year outcomes in patients with left ventricular ejection fractions ≤40%, 41% to 49%, and ≥50% having percutaneous coronary revascularization
    Keelan, PC
    Johnston, JM
    Koru-sengul, T
    Detre, KM
    Williams, DO
    Slater, J
    Block, PC
    Holmes, DR
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (10) : 1168 - 1172